Extract from the above information

The specific pharmacological effects are not described in detail from the above information.

This product is an angiotensin II (AngI) receptor inhibitor, which can specifically antagonize angiotensin converting enzyme 1 receptor (AT1). Its antagonism to ATI is greater than AT28500 times. It selectively blocks the binding of AngII to AT1 receptor, inhibits vasoconstriction and the release of aldosterone, and produces a hypotensive effect. This product does not inhibit angiotensin converting enzyme (ACE), renin, other hormone receptors, nor does it inhibit ion channels related to blood pressure regulation and sodium balance.

Itaquinoxaline is a non-peptide angiotensin II (AⅡ) receptor antagonist that can bind to the AⅡ receptor subtype AT1 with high selectivity and specificity, thereby blocking AⅡ activity.

Relax vascular smooth muscle, activate guanylate cyclase by releasing nitric oxide (NO), increase cyclic guanosine monophosphate (cGMP) in smooth muscle cells, thereby dilating peripheral arteries and veins, and having a stronger dilating effect on veins. Reduce the amount of blood returning to the heart, reduce left ventricular end-diastolic pressure and pulmonary capillary wedge pressure (preload), reduce peripheral vascular resistance, systolic arterial pressure and mean arterial pressure (afterload), increase coronary artery perfusion, reduce myocardial oxygen consumption, increase oxygen supply, and relieve angina pectoris.